Silence Therapeutics (NASDAQ:SLN) (NASDAQ:SLN) is a global biotechnology company focused on the discovery and development of small interfering RNA (siRNA) therapeutics designed to silence disease-causing genes. Since its founding in 1996, the company has leveraged its proprietary ESC-GalNAc delivery platform to advance a pipeline of novel therapies targeting cardiovascular, metabolic and rare genetic diseases. Silence Therapeutics is headquartered in London, U.K., with additional research and development operations in Boston, Massachusetts.
The company’s core business activities center on the identification and validation of genetic targets, followed by the design, synthesis and preclinical evaluation of siRNA molecules conjugated to N-acetylgalactosamine (GalNAc) to ensure efficient delivery to the liver. Its lead clinical candidates include SLN124 for iron overload disorders, SLN360 for cardiovascular risk reduction and SLN500 series candidates for metabolic conditions. Silence has also established strategic partnerships and licensing agreements with biopharmaceutical collaborators to accelerate the development of its pipeline across multiple therapeutic areas.
Silence Therapeutics conducts early- and mid-stage clinical trials across Europe and North America, working closely with regulatory authorities to align development programs with regulatory requirements. The company’s integrated research and clinical infrastructure supports rapid translation from discovery to clinic, while partnerships with contract research organizations and academic institutions extend its reach into special patient populations and rare disease communities. By focusing on liver-targeted RNAi, Silence aims to address unmet medical needs in areas with high barriers to treatment.
The company is led by Chief Executive Officer Bill Malcolm, whose background spans clinical development and strategic alliances in the biotechnology sector. The executive team comprises experienced professionals in RNA biology, drug delivery, regulatory affairs and commercial planning, supported by a Board of Directors with deep expertise in life sciences innovation. Under this leadership, Silence Therapeutics pursues a disciplined approach to advancing its pipeline toward regulatory milestones and potential commercialization.
